Executive Summary: The Headline
- Solid top-line and reported profit growth: Revenue +10.5% YoY to ₹15,300 Cr. Reported PAT +27% YoY to ₹2,895 Cr. Adjusted PAT +3.1% to ₹3,089 Cr.
- India and Specialty drove performance: India Formulations grew 16% YoY. Global Innovative Medicines grew 12.8%. US Formulations declined.
- Overarching narrative: A steady quarter for India’s largest pharma company. Strong domestic growth and specialty momentum offset weakness in the US generics business and some margin pressure. The Organon acquisition remains on track.
1. Key Financial Highlights
Key Metrics Summary (Consolidated)
| Metric | Q1 FY27 | YoY | Comments |
|---|---|---|---|
| Revenue | ₹15,300 Cr | +10.5% | Steady growth |
| Reported PAT | ₹2,895 Cr | +27% | Boosted by lower exceptions |
| Adjusted PAT | ₹3,089 Cr | +3.1% | Underlying growth |
| EBITDA | ₹4,418 Cr | +2.7% | Modest |
| EBITDA Margin | 28.9% | -220 bps | Contracted |
Business Highlights:
- India Formulations: +16% YoY to ₹5,475 Cr (36.1% of sales). Market share improved to 8.5%.
- Global Innovative Medicines: +12.8% YoY; contributed ~22% of sales.
- US Formulations: Declined ~9.7% YoY.
- R&D spend: ₹826 Cr (5.4% of sales).
- Organon acquisition-related charges impacted the quarter; deal remains on track for early 2027.
- Five new products launched in India during the quarter.
2. Comparison with Market Estimates
Results were broadly in-line to slightly mixed:
- Revenue growth of 10.5% was largely in line / slightly below some elevated expectations.
- Reported PAT growth was strong due to lower exceptional items.
- Adjusted profit growth was modest.
- Margin contraction was expected given higher investments and mix.
- Overall: Clean operational performance led by India and specialty.
3. Brokerage Notes & Target Prices
Initial reaction is expected to be neutral to mildly positive.
- Sun Pharma continues to be valued for its India leadership and growing specialty/innovative portfolio.
- Brokerages will focus on the sustainability of India growth, specialty ramp-up, US generics recovery, and the Organon integration timeline.
- Long-term thesis remains intact around specialty transition and domestic strength.
4. Management Commentary Highlights
- Quarterly performance driven by strong growth in India and the Innovative Medicines business.
- Continued focus on specialty and innovative portfolio expansion.
- Organon acquisition progressing as planned.
- R&D investments remain elevated to support the pipeline.
- Tone: Confident on the India and specialty growth engines; cautious on the US generics environment.
Forward-looking evaluation: Management is expected to reiterate focus on specialty growth and domestic market leadership while navigating regulatory and competitive pressures in the US.
5. Positives and Concerns
Positives:
- Strong 16% growth in India Formulations.
- Innovative/Specialty business growing in double digits.
- Market share gains in the domestic market.
- Reported PAT growth of 27%.
- Organon acquisition on track.
- Healthy R&D investment supporting future pipeline.
Concerns:
- EBITDA margin contracted by 220 bps.
- US Formulations declined nearly 10%.
- Adjusted profit growth was modest (+3%).
- Higher operating expenses and acquisition-related costs.
- Competitive and pricing pressure in the US generics market.
- Ongoing regulatory risks in key markets.
6. Possible Market Reaction
Short-term view (next 1-5 days): Neutral to mildly positive / range-bound. Stock may open flat to modestly higher. The strong India performance is a positive, but margin pressure and US weakness may limit aggressive upside in the near term.
Immediate Sentiment: Cautiously positive / wait-and-watch.
The “Why”: Investors in Sun Pharma prioritise the quality of growth (India + Specialty) and margin trajectory. This quarter delivered on the former but showed pressure on the latter.
Key Catalyst for Traders: India Formulations +16% and Innovative Medicines +12.8% — these are the key positives supporting the long-term narrative.